This heterogeneity opens up the possibility that signalling differences recognized between different mutant types in TP53 may also result in characteristic metabolic shifts, opening up a further research avenue of drug sensitivity and prognostic value for metabolism in TP53 mutant cancer. The gene discussed is TP53; the disease is cancer.